Evommune (EVMN) Income from Continuing Operations (2024 - 2026)
Evommune (EVMN) reported Income from Continuing Operations of 21674000.0 for Q1 2026, down 50.18% year-over-year from 43504752.16 in Q1 2025, and up 23.34% quarter-over-quarter from 28273000.0 in Q4 2025.
Evommune (EVMN) Income from Continuing Operations (2024 - 2026) Analysis & Trends
Evommune (EVMN) has 3 years of Income from Continuing Operations data on file, last reported at 21674000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 21674000.0, down 50.18% year-over-year; the trailing twelve-month figure through Mar 2026 was 76854000.0 (changed N/A YoY), and the FY2025 annual result was 77798000.0, down 16.45% from the prior year.
- Income from Continuing Operations improved to 21674000.0 in Q1 2026 per EVMN's latest filing, from 28273000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 12475000.0 in Q3 2025 and troughed at 28273000.0 in Q4 2025.
- A 3-year average of 18916000.0 and a median of 18321000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations gained 21.62% in 2025, then slumped 50.18% in 2026.
- A 3-year view of Income from Continuing Operations shows it stood at 20726000.0 in 2024, then sank by 36.41% to 28273000.0 in 2025, then climbed by 23.34% to 21674000.0 in 2026.
- Business Quant data shows EVMN's Income from Continuing Operations at 21674000.0 in Q1 2026, 28273000.0 in Q4 2025, and 12475000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Evommune | 695.29 Mn | 483.82 Mn | - | -21.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.67 Mn |
| Dec 31, 2025 | -28.27 Mn |
| Sep 30, 2025 | -12.48 Mn |
| Mar 31, 2025 | -14.43 Mn |
| Dec 31, 2024 | -20.73 Mn |
| Sep 30, 2024 | -15.92 Mn |